key: cord-0897983-3kfr1f9n
authors: Douin, David J.; Shaefi, Shahzad; Brenner, Samantha K.; Gupta, Shruti; Park, Isabel; Wright, Franklin L.; Mathews, Kusum S.; Chan, Lili; Al-Samkari, Hanny; Orfanos, Sarah; Radbel, Jared; Leaf, David E.
title: Tissue Plasminogen Activator in Critically Ill Adults with COVID-19
date: 2021-03-30
journal: Annals of the American Thoracic Society
DOI: 10.1513/annalsats.202102-127rl
sha: df7c07fabe44ffe7dec80ff62d0e34f1436ce241
doc_id: 897983
cord_uid: 3kfr1f9n

nan

To the Editor:

Hypercoagulability may be a key factor leading to multiorgan failure and death in critically ill patients with coronavirus disease (COVID-19) (1) . Extensive pulmonary microthrombi have been described in patients with acute respiratory distress syndrome from COVID-19 (2, 3) . These observations have prompted some clinicians to advocate for the use of fibrinolytic therapy with recombinant tissue plasminogen activator (tPA) in select critically ill patients with COVID-19 (4, 5) , yet sparse data on safety and efficacy are available (6, 7) .

We used data from STOP-COVID (Study of the Treatment and Outcomes in Critically Ill Patients with COVID-19), a multicenter cohort study of critically ill adults with COVID-19 admitted to 68 geographically diverse hospitals across the United States, to examine the safety and efficacy of tPA in this setting (8) . We included patients from the STOP-COVID registry admitted to intensive care units (ICUs) between March 1 and July 1, 2020, who received tPA for confirmed pulmonary embolism (PE) or suspected PE or pulmonary microthrombi within 14 days after ICU admission. Patients were followed until hospital discharge or death.

The primary safety endpoint was major bleeding within 7 days of tPA administration, defined as bleeding within a critical area or organ (e.g., intracranial, retroperitoneal, pericardial, or intramuscular bleeding with compartment syndrome) or bleeding requiring a procedural intervention (9) . The primary efficacy endpoint was change in the ratio of partial pressure of arterial oxygen to fraction of inspired oxygen (Pa O 2 :FI O 2 ) before and after tPA administration. Secondary efficacy endpoints were the proportion of patients who required therapies for refractory hypoxemia (prone position, neuromuscular blockade, or inhaled pulmonary vasodilators), the proportion of patients with an increase in the Pa O 2 :FI O 2 ratio >50% after tPA administration, and the change in the vasoactive-inotropic score (VIS) in the first 24 hours after tPA administration (10) (11) (12) . We collected data on the Pa O 2 :FI O 2 ratio from the closest arterial blood gas obtained within 48 hours before tPA and the first three arterial blood gases within 48 hours after tPA receipt. We collected VIS data immediately before and at 6, 12, and 24 hours after tPA receipt.

Among 5,154 patients enrolled in STOP-COVID, 93 (1.8%) received tPA. We excluded patients who received tPA for intracatheter thrombosis (n = 28), peripheral arterial thrombosis (n = 2), ischemic stroke (n = 2), myocardial infarction (n = 1), or catheter-directed thrombolysis (n = 1), leaving a total of 59 patients (from 16 institutions) included in this analysis.

Baseline characteristics of these 59 patients (1.1% of the parent cohort) are shown in Table 1 Six patients (10.2%) experienced a major bleed within 7 days after tPA administration, four of whom (67%) bled within 2 days of tPA receipt ( Table 2 ). Sites of major bleeding included the bronchopulmonary tree (n = 2), central nervous system (n = 1), gastrointestinal tract (n = 1), and mucocutaneous (n = 2). Among the six patients with a major bleed, five (83.3%) were receiving therapeutic anticoagulation at the time of tPA receipt ( Table 2 ). All six patients with a major bleed died (median time from tPA receipt to death, 7 days [IQR, [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] ).

Oxygenation and ventilation parameters were unchanged after tPA receipt, as was the proportion of patients who required therapies for refractory hypoxemia (Table 1) . Similarly, tPA did not affect the Pa O 2 :FI O 2 ratio longitudinally, either overall or in two prespecified subgroups: those with severe hypoxemia (Pa O 2 :FI O 2 ,100) and D-dimer .10,000 ng/ml (13) at the time of tPA receipt ( Figure 1 ). Results were similar when patients who received tPA during cardiac arrest were excluded. Pa O 2 :FI O 2 ratio increased by >50% in only 8 of 42 patients (19.0%) with data available (Table 1) . tPA also did not affect the amount of hemodynamic support as quantified by the VIS (Table 1) .

In summary, we report the outcomes of 59 critically ill patients with COVID-19 who received fibrinolytic therapy with tPA. Despite the promising theoretical benefits of fibrinolytic therapy in COVID-19, administration of tPA did not improve oxygenation or hemodynamics in the patients in our cohort. We Definition of abbreviations: BMI = body mass index; COPD = chronic obstructive pulmonary disease; ICU = intensive care unit; IQR = interquartile range; Pa CO 2 = partial pressure of carbon dioxide; Pa O 2 :FI O 2 = ratio of partial pressure of arterial oxygen to fraction of inspired oxygen; tPA = tissue plasminogen activator; VIS = vasoactive-inotropic score; VV-ECMO = venovenous extracorporeal membrane oxygenation. *Oxygenation and ventilation values before and after tPA are derived from the closest arterial blood gas obtained within 48 hours before and after tPA receipt, respectively. These data were available for 42 of the 59 patients (71.2%) in the cohort. † Therapies for refractory hypoxemia and number of vasopressors before and after tPA were assessed within 24 hours before and 24 hours after tPA receipt, respectively. ‡ Inhaled pulmonary vasodilators include epoprostenol and nitric oxide. § Patients may have had more than one cause of death. jj A total of 17 patients were previously reported: 15 in a single-center case series by Orfanos and colleagues (6) and 2 in a single-center case series by Barrett and colleagues (7) .

found that major bleeding occurred in 6.8% of patients within 2 days of tPA administration and in 10.2% of patients within 7 days, all of whom died. Although a control arm was not available to directly compare bleeding risk in patients with similar disease severity who did or did not receive tPA, rates of major bleeding in this study were similar to those previously reported with tPA (14) . Interestingly, five of the six patients who experienced a major bleed were receiving therapeutic anticoagulation at the time of tPA receipt, suggesting the combination of these two therapies may result in a particularly high risk of bleeding.

We acknowledge several limitations, including observational design, absence of a control group, and heterogeneity of patients and tPA dosing regimens. Patients in this cohort were severely ill, with a median Pa O 2 :FI O 2 ratio , 100 ) values for the ratio of the partial pressure of arterial oxygen to fraction of inspired oxygen (Pa O 2 :FI O 2 ) before and after tPA receipt. "21" represents the closest Pa O 2 :FI O 2 ratio obtained within 48 hours before tPA receipt. "11," "12," and "13" represent the first three Pa O 2 :FI O 2 ratios obtained within 48 hours after tPA receipt. The median time from the "21" Pa O 2 :FI O 2 ratio to tPA administration was 2.4 hours (IQR, 1.0-6.2). The median time from tPA administration to the "11," "12," and "13" Pa O 2 :FI O 2 ratios was 3.0 (IQR, 1.3-9.1), 11.3 (IQR, 6.0-23.0), and 17.5 (IQR, 10.0-32.6) hours, respectively. The number of patients in the "All" category (n = 42) is less than 59 because 17 patients (28.8%) did not have arterial blood gas measurements obtained within 48 hours before and after tPA receipt.

at the time of tPA receipt, a substantial number who required therapies for refractory hypoxemia, and a 76% in-hospital mortality rate. Indications for tPA administration were assessed via manual chart review; however, documentation of precise clinical decision-making was not always reliably captured. Arterial blood gases were not obtained at standardized time points, and factors such as changes in positioning (i.e., prone vs. supine) could have had an important influence of the Pa O 2 :FI O 2 ratio in ways that were not captured by our data set. Many clinicians may have administered fibrinolytic therapy as an emergency treatment to save patients who were already dying. In fact, 10% of patients received tPA during a cardiac arrest. It is likely that some of the major bleeding events, particularly those detected more than 2 days after tPA administration, may have been due to other factors, particularly given the short half-life of tPA.

The possibility that tPA may confer benefits to select patients with COVID-19, perhaps if administered earlier in the disease course or to a more homogeneous group of patients, remains unknown. Randomized clinical trials of tPA in severely ill patients with COVID-19 (NCT04357730) will shed much needed light on the efficacy and safety of tPA in this setting.

Hypercoagulability of COVID-19 patients in intensive care unit: a report of thromboelastography findings and other parameters of hemostasis

Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans

Clinical pathology of critical patient with novel coronavirus pneumonia (COVID-19)

Fibrinolytic therapy for refractory COVID-19 acute respiratory distress syndrome: scientific rationale and review

Study of alteplase for respiratory failure in SARS-Cov2/COVID-19: study design of the phase IIa STARS trial

Observational study of the use of recombinant tissue-type plasminogen activator in COVID-19 shows a decrease in physiological dead space

Rescue therapy for severe COVID-19-associated acute respiratory distress syndrome with tissue plasminogen activator: a case series

STOP-COVID Investigators. Factors associated with death in critically ill patients with coronavirus disease 2019 in the US

ANNEXA-4 Investigators. Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors

Vasoactive-inotropic score as a predictor of morbidity and mortality in infants after cardiopulmonary bypass

Prognostic value of vasoactive-inotropic score following continuous flow left ventricular assist device implantation

Validation of the vasoactive-inotropic score in pediatric sepsis

Never ignore extremely elevated D-dimer levels: they are specific for serious illness

Thrombolysis for pulmonary embolism and risk of all-cause mortality, major bleeding, and intracranial hemorrhage: a meta-analysis

Author disclosures are available with the text of this letter at www.atsjournals.org. *Corresponding author (e-mail: david.douin@cuanschutz.edu). ‡ These authors contributed equally to this work. § These authors contributed equally to this work.